ACADIA Pharmaceuticals Inc.

NasdaqGS ACAD

ACADIA Pharmaceuticals Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.78

ACADIA Pharmaceuticals Inc. EPS (Diluted) is USD 0.78 for the Trailing 12 Months (TTM) ending September 30, 2024, a 184.49% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

ACADIA Pharmaceuticals Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.92, a 31.61% change year over year.
ACADIA Pharmaceuticals Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.35, a -12.50% change year over year.
ACADIA Pharmaceuticals Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.20, a 30.23% change year over year.
ACADIA Pharmaceuticals Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.72, a 2.27% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGS: ACAD

ACADIA Pharmaceuticals Inc.

CEO	Ms. Catherine E. Owen Adams
IPO Date	May 27, 2004
Location	United States
Headquarters	12830 El Camino Real
Employees	620
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Key trends

Past 5 years